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This short review aims at highlighting new trends in polymer science towards the design
of bioactive and biofunctional materials by design. The recent development of controlled
polymerization and post-modiﬁcation methods together with efﬁcient coupling strategies
based on “click chemistry” approaches allows the preparation of highly precise polymer
systems that combine the ability to self-assemble into well-deﬁned and predictable
structures, together with a pre-deﬁned or molecularly encoded bioactivity (such as
interaction, inhibition, recognition). Even if polymers have been used for many years in the
ﬁeld of biomaterials mostly because of their mechanical properties and inert character, we
believe that a novel area is arising, where polymers will be at the center of innovation.
Such highly precise polymer materials are believed to bring breakthrough technologies at
the interface between materials science and biotechnology.
© 2015 Academie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).r é s u m é
Cette courte revue a pour but de donner au lecteur un point de vue sur de nouvelles
tendances qui emergent en science des polymeres, dans le domaine des materiaux bio-
actifs et biofonctionnels. Les developpements recents en polymerisation contro^lee, post-
modiﬁcation des polymeres et de methodes de couplage par « chimie click », en par-
ticulier, permettent aujourd’hui le design de polymeres de precision capables de combiner
dans leur structure macromoleculaire a la fois les informations pour s’auto-assembler de
façon predictible et contro^lee et des proprietes de bioactivite (interaction, inhibition,
reconnaissance, etc.). Ainsi, et me^me si les polymeres sont utilises depuis de nombreuses
annees dans le domaine des biomateriaux, principalement pour leur absence de toxicite et
leur furtivite, une nouvelle ere a commence, où les polymeres seront a l’origine des futures
innovations de rupture a l’interface entre science des materiaux et biotechnologies.
© 2015 Academie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., LCPO, UMR 5629,
commandoux).
ed by Elsevier Masson SAS.1. Introduction
Polymers have become a major class of materials, with
constant growth in their production and use over the lastThis is an open access article under the CC BY-NC-ND license (http://
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properties, lightweight, low cost, and recycling capability.
Polymer materials, that have smoothly replaced metals,
ceramics, wood, etc. in many end products over the last ﬁfty
years, are now strategic compounds in the chemical in-
dustry. Polymers are currently found everywhere in our
everyday life: e.g., in the transport industry (car, aerospace,
military…), in constructions, in the sport and leisure in-
dustries, in healthcare, and so on.
For many years, synthetic polymers have been obtained
from the polymerization of one monomer, leading to ho-
mopolymers. In order to combine several properties in
polymer materials, polymer mixtures can be synthesized.
However, due to the strong chemical incompatibility be-
tweenpolymer chains, such a strategy is very limited due to
the resultant macroscopic phase separation observed. Co-
polymers, resulting from the polymerization of two or more
monomer units into a single chain, have been developed
and have solved this problem. These can be statistical, block
or grafted amongst the simplest structures. Due to
continuous progress in the development of controlled
polymerization methods, together with the evolvement of
characterization methods down to the nanoscale and
improvement of theoretical understanding, deep control of
copolymers microphase separation and correlations with
their macromolecular structure can now be performed.
Remarkably, block copolymers can spontaneously self-
assemble into micro- or nanostructures with controllable
and predictable sizes, shapes andmorphologies. As a result,
block copolymers are seen nowadays as the most sophis-
ticated polymer structures, allowing innovative approaches
in materials science-related industries (e.g., optics, elec-
tronics, energy, compliance) [1].
In the biomedical and biomaterials ﬁelds, due to their
biocompatibility and biodegradability in the case of poly-
esters, polycarbonates or polypeptides for instance, poly-
mers are widely used for many different tools, such as
catheters, surgery plaques and screws, as well as scaffolds
for tissue engineering or drug delivery [2]. For all these
applications, their major asset is their inert behavior
(stealthiness) towards the immune and reticulo-
endothelial systems. However, even though polymers
have already brought breakthrough technologies in medi-
cine (e.g., surgery, implants, delivery systems), allowing
remarkable beneﬁts for the patient, rather simple polymer
structures have been used and developed so far. One can
anticipate in a near future great improvement with more
sophisticated polymers presenting integrated biological
functions playing an active role in the ﬁnal outcome (e.g.,
full integration into biological tissues).
In order to progress towards this goal, a straightforward
strategy in polymer design would be to explore polymers
that can encode multiple functions and activity, thus
mimicking natural polymers such as nucleic acids (DNA,
RNAs), proteins, and glycans that are produced and used
everyday in natural living systems. These are involved in a
myriad of biological processes in vivo, in physiological or
pathological circumstances, including among many others
cell signaling and regulation. The level of precision in their
chemical composition and structure exceeds by far what
can be synthetically achieved nowadays. The latter ishowever critical for proper operation: for instance in the
case of proteins, the control of the monomer sequence
(namely the protein primary structure) is governing the
protein conformation (secondary structure) and assembly
(tertiary and quaternary structures) that are critical for the
resulting bioactivity.
The aim of the present contribution is to highlight
emerging synthetic strategies that we believe will bring
signiﬁcant beneﬁt and breakthrough technologies in the
biomedical or biomaterials areas. We will illustrate our
thoughts with several chosen examples and do not pretend
to provide the reader with an exhaustive view of this
research ﬁeld, but rather with a personal point of view. Our
idea is especially to focus on polymer systems that have
been precisely designed to interact with biological micro-
environments and used to get a deeper understanding of
their interaction mechanism or to establish clear structur-
eeactivity relationships. Wewill illustrate several synthetic
approaches that are being developed in this context,
including (Fig. 1): 1) synthetic polymer chemical modiﬁ-
cations, 2) design of biohybrid macromolecules, and 3)
recombinant production of bio-engineered polymers.
2. Bioactive properties via synthetic polymer
chemical modiﬁcations
For many years, bioactive polymers were fully biocom-
patible such as hyaluronan widely used in regenerative
medicine strategies or those presenting non-fouling or
protein-repellant properties such as poly(ethylene oxide)
PEO or poly(ethylene glycol) PEG used in drug delivery. The
propensity of PEG polymer chains or brushes at the inter-
face to avoid/limit adsorption of plasmatic proteins has
been studied for many years. The term “pegylation” is even
popularly accepted, implying the PEG conjugation as a
“magic” approach to provide stealth properties to any
system, which is absolutely wrong! One has not to forget
the basic principles of physics beyond the effect of “pegy-
lation” that are a high hydration rate and optimal entropic
repulsion of PEG chains [3]. In the same line, aiming at
designing surfaceeactive materials, polymers with anti-
bacterial properties have been developed. Antimicrobial
polymers can provide protection against a variety of path-
ogenic bacteria, by analogy with their peptide analogs that
are part of the innate immune system. Over the past
decade, there have been signiﬁcant efforts in developing
antimicrobial polymers that could be used as bioactive
surfaces or as intravenously administered antibiotics [4]. Li
and Yang have proposed promising examples of the use of
synthetically modiﬁed cell-penetrating peptides (CPPs)
resulting in self-assembled nanoparticles capable of
crossing the bloodebrain barrier and suppress bacterial
growth in infected brains [5]. However, despite consider-
able investment in the pharmaceutical and biotechnology
industries, this strategy drudges to come true, mainly due
to the lack of understanding of the underlying mechanisms
involved in living systems. Learning how to program syn-
thetic polymers with the appropriate chemical information
to effectively capture the biological activity of peptides or
proteins will be critical to better understand their mecha-
nisms. For instance, Tew and coll. recently developed an
Fig. 1. Strategies to prepare bioactive block copolymers.
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opening polymerization of norbornene-derivatives to
study the balance between charge and hydrophobic in-
teractions that are involved in CPP mechanisms [6]. The
development of such synthetic tools that can facilitate
establishing relevant structureeactivity relationships is
particularly important in the ﬁeld, as bacterial resistance is
becoming a huge public health concern.
In the ﬁeld of drug delivery, nanoparticles resulting
from the self-assembly of amphiphilic block copolymers
are proving to be compelling. This ﬁeld beneﬁted from the
most advanced synthetic developments. Amphiphilic and
stimuli-responsive polymer nanoparticles have been
designed in the last decade, using every existing controlled
polymerization method. The incorporation of building
blocks with tunable properties under different speciﬁc
conditions (e.g., pH, enzyme, temperature, magnetic ﬁeld,
ultrasound, X-rays) has allowed the design of many
different systems capable of releasing their payload in a
controlled manner [7]. Current developments mainly aim
at targeting speciﬁc cells, cellular microenvironments or
organs, en route to personalized medicine. Targeting
properties can indeed be subsequently endowed to self-
assembled polymer nanoparticles by surface grafting of
biologically validated receptor-speciﬁc ligands (e.g., sac-
charides, peptides, full antibodies or fragments, aptamers,
low-molecular weight organic molecules) [8]. However,
this strategy involves block copolymer synthesis, self-
assembly processing and post-modiﬁcation functionaliza-
tion with the targeting moiety. Even though such an
approach is very smart and some systems are currently in
phase III clinical trials [9], one can anticipate that scalability
and batch-to-batch reproducibility may become tricky
when multiple functionalities have to be independently
incorporated into self-assembled nanoparticles. One of the
critical point is to develop synthetic methods that are
precise enough to clearly enable structureeactivity re-
lationships with perfect reproducibility and useful foun-
dation that can be transferred to any other polymer system.3. Biohybrid macromolecules
In order to overcome the previously mentioned limita-
tions, one particularly relevant approach consists indesigning materials that encode both self-assembly and
biological functionalities at the molecular level, similarly to
naturally occurring molecules that form biological self-
assemblies. Especially interesting are biohybrid macro-
molecules that combine useful features of block co-
polymers (i.e., self-assembly propensity) with those of
natural and bioactive biopolymers, such as polypeptides,
proteins, polysaccharides, and glycans.
Many natural macromolecules have already been iden-
tiﬁed for their intrinsic biological activity, among which
peptides and proteins represent a wide class. Polymer-
peptide biohybrids can be obtained by covalently attach-
ing biologically relevant peptides to synthetic polymer
chains to form amphiphilic polymer-peptide conjugates.
The latter thus possesses self-assembly properties arising
from the amphiphilic character and those afforded by the
peculiar nature of the polymer block, while the peptide
moiety confers surface bioactivity to the resulting self-
assembled micellar or vesicular structures [10]. Our group
has also contributed to this area, with the design of Tat-b-
PTMC biohybrids, featuring a biocompatible poly(tri-
methylene carbonate) (PTMC) polymer segment and the
Tat47e57 sequence from HIV-1 transcription transactivator
protein (TAT), with well-established cell-penetrating
properties, in order to access nano-assemblies speciﬁcally
dedicated to cellular internalization. Presenting a Tat-rich
corona, strongly positively charged, the resulting micelles
not only presented notable cell transduction ability, but
also substantial toxicity. Micelles with controlled sizes and
Tat surface density were designed to point out the impact
of micellar engineering on the surface of nanoparticles, and
to clarify their internalization mechanism [11].
Oligosaccharides and polysaccharides represent also an
interesting class of bioactive biopolymers, even if their
synthesis, puriﬁcation and chemical modiﬁcation are
complex. Among them, chitosan, heparin and hyaluronan
are the most studied [12]. Chemical modiﬁcations, mostly
via side-chain grafting, allowedmodulation of their activity
and solubility, allowing the formation of self-assembled
structures in some cases. Glycopolymer synthesis has also
been widely developed to introduce low-molecular weight
carbohydrate epitopes on polymer chains obtained by
living/controlled polymerization methods [13]. Only a few
studies mentioned the use of polysaccharide-block
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erties. Kalin et al. actually envision that polysaccharide-
block copolymers shall constitute an excellent alternative
to polysaccharide-protein conjugates that are developed as
immunizing antigens to produce carbohydrate-directed
antibodies or as antigens in immunoassays [14]. More
recently, efﬁcient coupling strategies, namely “click
chemistry”, allowed the design of precise amphiphilic
linear diblock copolymer structures with oligosaccharides.
Hyaluronan has been mainly studied because of its ability
to recognize CD44 glycoproteins that are involved in many
diseases, including cancer and inﬂammation. Hyaluronan
has especially been coupled to poly(g-benzyl glutamate)
via Huisgen cycloaddition [15] and to poly(D,L-lactide-co-
glycolide) via peptide coupling [16]. In both cases, in vitro
and in vivo targeting ability of the resulting nanoparticles
has been demonstrated on CD44-expressing cells, together
with encouraging tumor regression preclinical proofs of
concept. These results, demonstrated the relevance of the
concept of “self-targeting nanoparticles”, implying that the
targeting property is directly encoded into the polymer, by
using a hydrophilic segment that has simultaneously the
capacity to provide colloidal stability and to target speciﬁc
cellular receptors. Such a concept can potentially be
extended to any other oligosaccharides, peptides, proteins
or nucleic acids that can provide at least two functions
(colloidal stability and bioactivity), the bioactivity being of
various nature (e.g., targeting, inhibition, activation or
agonist/antagonist properties for a receptor).
Nevertheless, even though such a strategy is very
elegant, promising and even currently in pharmaceutical
development [17], it is limited to biomolecules with sufﬁ-
cient hydrophilicity, that allow chemical coupling to
another polymer segment using high efﬁcient coupling
strategies and retain their bioactivity after conjugation.
Again, the development and optimization of such polymer-
based biohybrid systems will require signiﬁcant efforts in
order to guarantee a perfect reproducibility due to the
intrinsic polydispersity of polymer chains and possibly the
biological synthons.
4. Recombinant polymers
To obviate from the previous limitations, material sci-
entists have started in the past decade to turn towards
protein-engineering techniques and to produce de novo
protein-like polymers from recombinant methods. Mainly
constituted from repeating peptide sequences, these mac-
romolecules have received different names from their in-
vestigators such as “protein polymers”, “recombinant
polymers”, or even “recombinamers” [18]. The principle is
based on the design of an artiﬁcial gene encoding for the
complete macromolecule, including structural polymeric
sequences and speciﬁc peptide motifs featuring the desired
biological activities (receptor binding, pH-responsive,
cross-linking, enzyme-responsive motifs, etc.) placed at
appropriate locations into the protein polymer structure.
Among the signiﬁcant advantages of the method are: i) the
great freedom in material design arising from the inﬁnite
combinations of amino acid building blocks; ii) the mono-
dispersity and perfect control over sequence and length incontrast with chemically synthesized polymer materials;
and iii) the scalability to large and/or continuous batches
with a perfect reproducibility. Importantly, such a precision
in the polymer structure enables perfectly reliable struc-
tureebioactivity relationship studies.
Over the last decade, several classes of recombinant
polymers have been developed and studied, mostly elastin-
like polypeptides (ELPs), silk and silk-like proteins (SLPs)
and combination thereof, namely silk-elastin-like protein
polymers (SELPs), with the aim of designing bioactive
nanoparticles and hydrogels [19]. With the speciﬁc aim of
developing drug delivery systems, most recombinant
polymers studied are based on the pentapeptide repeat
[-VPGXG-] derived from the hydrophobic domain of elastin.
These ELPs indeed present a unique lower critical solution
temperature (LCST, also designated as ITT or Tt) that has a
dual beneﬁt: ﬁrstly, the LCST constitutes a means to control
the self-assembly process, a critical issue when working
with peptide and protein-materials; secondly, the LCST
greatly facilitates isolation and puriﬁcation of the protein
product out of the protein lysate soup. Since the ﬁrst
diblock ELP, featuring consecutive hydrophilic and lipo-
philic blocks, self-assembled into nanometer-sizedmicelles
described by Conticello and coworkers [20], signiﬁcant
advances have been made. Comprehensive studies on ELP
block copolymer design have evidenced critical parameters
(hydrophilic-to-hydrophobic block ratio, copolymer size,
distribution of polar and apolar regions along the polymer
chain, cross-linking) to obtain stable monodisperse core-
shell nanoparticles [21]. Temperature responsiveness has
been identiﬁed as a hallmark to trigger site-speciﬁc tar-
geting and accumulation of ELPs both in vitro and in vivo
[22]. The possibility to increase material complexity and to
display bioactive peptide motifs onto the surface of ELP
nanoparticles has also been demonstrated. Chilkoti and
coll. for instance described a recombinant diblock ELP
preceded by the avb3 integrin-targeting linear GRGDS
sequence turning from a low-avidity state as an unimer
into a multivalent high-avidity ligand above its critical
micelle temperature (CMT) [23]. Using ELPs as drug car-
riers, high molecular weight hydrophilic ELPs have also
been conjugated at their C-terminal end to hydrophobic
doxorubicin derivatives, inducing self-assembly into a
drug-rich core surrounded by a soluble protein corona.
In vivo, the drug-nanoparticle formulation had a fourfold
higher maximum tolerated dose (MTD) than doxorubicin
and induced nearly complete tumor regression after a
single systemic dose [24].
5. Conclusions
En route for highly functional biomaterials and nano-
devices, amphiphilic block copolymer structures are gain-
ing in complexity and precision in their macromolecular
structure. In addition to their intrinsic self-assembly
properties, they may include stimuli-responsiveness
possibly in addition to relevant biological functions. In
order to be used as model systems for the establishment of
structureebioactivity relationships, they however suffer
from some deviation in their chain-to-chain structure and
molar masses. If not necessarily an issue for the ﬁnal
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polymer structures during the development stages, for
better understanding and rational design. The recent
progress in precision and sequence-controlled polymeri-
zation methods may be an interesting approach, even
though limited so far to certain synthetic monomers [25].
DNA technologies and DNA-templating polymerization
methods can also present a high level of precision [26], but
are requiring the design of speciﬁc templates and mono-
mers with some limitations. The latest development e and
certainly one of the most promising and realistic for future
research and technology transfere involves the production
of protein-like polymers by protein engineering. Recom-
binant DNA techniques allow ﬁne-tuning of amino acid
positioning within the ﬁnal polymer product, thereby
enabling the incorporation of speciﬁc biological properties
(including degradation), in addition to imparting intrinsic
biocompatibility. We foresee that protein-polymer mate-
rials, with greater potential to echo the functional
complexity of native proteins, are prone to substitute for
traditional, synthetic polymers, highly regarded in the last-
century. Their biocompatibility and biodegradability into
natural metabolites (amino acids) are obvious advantages
towards biomedical applications. As recombinant protein
polymers do not require speciﬁc complex post-
translational modiﬁcations, their large scale-production
can be performed in E. coli at a lower cost considering
material's complexity in contrast with most recombinant
proteins currently used in the clinics (antibodies) that
require mammalian cell cultures. The perfect batch-to-
batch reproducibility of the material structure obtained
by such a process is also a key parameter for future clinical
and industrial developments. As for every technological
breakthrough, this approach mainly concerns the design of
high value-added materials. The potential impact is pro-
found for biomedical applications particularly in the area of
drug delivery, but also in biomaterials, tissue engineering
and regenerative medicine. We have no doubt that the
published literature in this domain, which has matured
dramatically in the last 5 years, will continue to exhibit
tremendous growth in the next few years involving a wide
range of scientiﬁc communities from polymer science to
colloidal science.Acknowledgements
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